RxDoctor Payments Data

Gary Belen, MD

Ophthalmology · Denver, CONPI 1841274933

Payments from drug & device makers

$3,128in general payments, 2019–2025

Across 94 payments — averaging $33.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Sight Sciences, Inc.$310
  • AbbVie$270
  • Bausch & Lomb Americas Inc.$257
  • Rxsight Inc$178
  • Johnson & Johnson Surgical Vision, Inc.$166
  • plus $698 from 10 others

What the payments were for

  • Food & beverage$3,04897%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,128 in reported general payments places this provider in the 70th percentile of 262 ophthalmology providers in Colorado.

See all ophthalmology providers in Colorado

Medicare billing

Part B allowed, 2024
$193,543
Medicare patients
375
Services billed
1,371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost43$30,123
RocklatanNetarsudil Mesylat/Latanoprost40$18,656
VyzultaLatanoprostene Bunod23$15,795
Prednisolone Acetate252$12,418
SimbrinzaBrinzolamide/Brimonidine Tart30$9,535
Travoprost51$8,503
Latanoprost722$7,309
Brimonidine Tartrate122$5,803
CombiganBrimonidine Tartrate/Timolol14$5,531
MoxifloxacinMoxifloxacin Hcl177$5,399
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$3,933
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat279$3,625
Dorzolamide-TimololDorzolamide/Timolol/Pf21$2,975
Timolol Maleate148$1,873
Ketorolac Tromethamine38$1,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$270$35,65457 claims
Aerie Pharmaceuticals, Inc.Rocklatan$61$18,65640 claims
Bausch & Lomb Americas Inc.Vyzulta$257$15,79523 claims
AlconSimbrinza$1,249$9,53530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 262 ophthalmology providers in Colorado.

Other ophthalmology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →